China Healthcare Procurement & Supply Chain Talent Trends 2026

Key Takeaways

• VBP is transforming procurement into a P&L defence function, not just a cost-saving role
• MAH is increasing accountability across outsourced manufacturing, especially in biotech
• License-out growth is driving demand for global-standard operational execution
• Talent gaps are not driven by availability, but by execution capability under complexity

 

Two parallel talent realities in China healthcare

Over the past three to five years, China's healthcare sector has split into two operating logics, each reshaping procurement and supply chain leadership hiring across China’s healthcare sector.
Top-tier domestic pharma is operating in a VBP (Volume-Based Procurement) and price corridor world, where the central business question is:

Biotech and CDMO are operating in an MAH plus outsourced manufacturing plus cross-border licensing world, where the question is: how do we govern external manufacturing and deliver global-grade execution once we sign license-out deals?

Based on DSJ Global’s work across China healthcare hiring mandates, a consistent pattern is emerging: leadership hiring is moving from expansion-led scaling to survival-oriented optimisation, with role compression and a widening gap between candidate availability and candidate effectiveness.

 

Part 1 — Top-Tier Domestic Pharma: VBP, Cost Down, and organisational Compression

VBP has permanently redefined the procurement mandate

China's National Volume-Based Procurement (NVBP/VBP) is designed to centralise purchasing power and reduce drug prices. It continues to evolve and influence both supplier selection and tender behaviours over time. For devices, similar dynamics have emerged as VBP has extended into MedTech categories, driving significant pricing disruption and forcing commercial model redesign.

For procurement teams inside domestic pharma, this is not a temporary headwind. It is the permanent operating environment.

Procurement is no longer a savings function. It has become a P&L defence function, expected to deliver:

• COGS transparency, meaning true cost breakdowns rather than negotiated savings stories
• BOM, formulation and packaging cost engineering tied to manufacturing realities
• Supplier consolidation and risk management through dual sourcing and continuity under tender volatility
• Tender-ready contracting discipline and supply assurance under compressed margins

 

The market wants business operators, not category negotiators

Domestic pharma is increasingly hiring procurement leaders who can operate like business operators, not only category negotiators.

DSJ Global is seeing consistent demand for should-cost capability, cost driver modelling and factory interface, procurement and finance interface covering cost waterfall and margin defence, and supplier governance with disciplined contract execution under tender constraints.

Should-cost capability and cost waterfall analysis are no longer niche skills. They are increasingly a baseline requirement at Director level and above.

 

organisational compression is now a hiring risk

In a VBP environment, many domestic players respond with headcount control and role consolidation. This creates super roles that combine multiple functions into one mandate. DSJ Global has highlighted this structural trend across China, and it is especially visible in healthcare due to margin pressure.

In practice, one role is increasingly asked to cover strategic sourcing and tender strategy, cost-down programmes and supplier negotiations, supply risk and inventory policy, and governance, process redesign and systems visibility.

This often produces longer search cycles and repeated shortlist failure, close-enough hiring followed by rapid scope renegotiation, and execution risk where role design is not aligned with talent reality.
Role design realism is becoming a competitive advantage. Clients who right-size mandates are closing searches faster and retaining hires longer.

 

Cost-down capability is being redefined

VBP forces companies to achieve savings beyond supplier price cuts, through localisation and substitution where compliant, packaging or specification redesign, yield, scrap and manufacturing interface work, and supplier capability improvement with stricter governance.

This is where procurement and supply chain become genuinely end-to-end, because savings must be real and sustainable rather than one-time.

 

High-demand talent archetypes in domestic pharma (2026)

• VBP Cost Defence Procurement Lead: should-cost modelling, tender strategy, governance
• Direct Materials Category Lead (API / excipients / packaging): cost drivers, dual sourcing, formulation interface
• Supplier Risk and Continuity Lead: capacity assurance, contract discipline, emergency playbooks

 

If you are hiring procurement or supply chain leaders in China healthcare, speak with DSJ Global's APAC team.

Request a call back →

 

Part 2 — Biotech and CDMO: MAH, Outsourced Manufacturing, and License-Out Backend Capability

MAH has forced biotech to own end-to-end accountability, even when outsourcing

China's MAH system formalised end-to-end accountability for drug quality and safety across the lifecycle, including when manufacturing is entrusted to third parties. This has driven clearer requirements for quality systems, key personnel responsibilities, traceability and oversight across development, manufacture, supply and post-marketing obligations.

The old assumption that outsourcing manufacturing removes the need for heavy operational infrastructure no longer holds. Under MAH expectations, outsourcing only works if the biotech can genuinely govern CDMO qualification and ongoing performance oversight, batch release governance and deviation/CAPA discipline, post-approval change control including comparability and site changes, and storage, transport oversight and recall readiness where applicable.

 

License-out is not just Business Development (BD) — it creates a backend execution obligation

The volume of outbound licensing from Chinese biotech has accelerated significantly, and global reliance on China-origin pipelines is increasing.

Once a biotech signs a license-out deal, global partners typically intensify expectations around manufacturing and QMS due diligence, tech transfer readiness and reproducibility of process data, audit readiness and documentation quality to global standards, and supply continuity for clinical and global development timelines.

DSJ Global is seeing a consistent pattern:

Chinese biotech companies with strong BD pipelines that are underinvested in operational execution capability.

The deal gets signed and the backend scramble begins. The companies winning in license-out are building operational credibility before they need it, not after the term sheet is signed.

 

CDMOs are upgrading — supply chain leaders must deliver audit-grade reliability

As MAH accountability expands and global partners demand higher operating maturity, CDMOs face multi-client scheduling and capacity commitments, higher audit frequency with genuine deviation/CAPA transparency and documentation quality, and supply continuity pressure under compressed timelines and single-source materials risk.

 

High-demand talent archetypes in biotech and CDMO in 2026

• External Manufacturing and Tech Transfer Lead: China and global standard fluency, CDMO governance
• Supplier Quality / Quality Systems Leader: vendor governance, audit readiness, CAPA authority
• Supply Chain Control Tower Lead: multi-site and multi-client, planning and inventory discipline

 

What This Means for Clients

For top-tier domestic pharma

organisations will outperform in 2026–2028 by hiring procurement leaders who can deliver engineered cost-down, not just negotiation outcomes.

organisational compression may look efficient on paper, but it often creates execution fragility. Role design realism is a competitive advantage.

 

For biotech and CDMO

Outsourcing does not reduce accountability under MAH. It increases it. Backend governance is now a core competence, not a regulatory formality. License-out success must be matched with operational capability across tech transfer, QMS, external manufacturing control and supply readiness.

 

The Constraint Is Not Availability — It Is Effectiveness

China healthcare procurement and supply chain talent is not constrained by availability. It is constrained by the number of people who can deliver under VBP margin compression, and leaders who can govern outsourced manufacturing under MAH while meeting global partner expectations after license-out.

That distinction matters enormously for how you design roles, set expectations and build search briefs.

To discuss hiring strategies or talent challenges in China healthcare procurement and supply chain, speak with DSJ Global’s APAC team.

Request a call back →

 

 

 

About DSJ Global

DSJ Global is a specialist executive search firm focused exclusively on end-to-end supply chain, procurement, operations and industrial leadership across China, Asia Pacific, the Middle East, Europe and North America. The firm partners with multinational corporations, industrial groups and PE-backed organisations to support critical leadership hiring, succession planning and long-term capability building across complex and highly regulated environments.

DSJ Global is part of the Phaidon International group. For clinical, regulatory and scientific leadership hiring across Asia Pacific, our life sciences specialist brand EPM Scientific supports end-to-end talent needs across the healthcare value chain.